- Investing Ideas
- Global Pharmaceuticals & Biotech Top Growth Stocks
Global Pharmaceuticals & Biotech Top Growth Stocks
Results
67
67 companies
Beijing Luzhu Biotechnology
Market Cap: HK$2.7b
A biotechnology company, develops human vaccines and therapeutic biologics to prevent and control infectious diseases, and to treat cancer and autoimmune diseases in Mainland China.
2480
HK$13.59
7D
-2.9%
1Y
-41.7%
Axsome Therapeutics
Market Cap: US$11.6b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$215.77
7D
1.7%
1Y
105.0%
Madrigal Pharmaceuticals
Market Cap: US$11.9b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$535.27
7D
5.5%
1Y
49.1%
TG Therapeutics
Market Cap: US$7.0b
A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
TGTX
US$49.90
7D
2.4%
1Y
84.0%
Oscotec
Market Cap: ₩1.4t
Operates as a biotechnology company, engages in the drug development, functional materials and related products, and dental bone graft material businesses.
A039200
₩37,400.00
7D
8.1%
1Y
18.7%
Camurus
Market Cap: SEK 37.0b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
CAMX
SEK 622.00
7D
3.4%
1Y
-2.1%
HansBiomed
Market Cap: ₩345.1b
Engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies.
A042520
₩24,200.00
7D
19.5%
1Y
182.7%
Guangzhou Innogen Pharmaceutical Group
Market Cap: HK$3.3b
Engages in the development of drug engaged in the research, development and commercialization of pharmaceutical products.
2591
HK$7.20
7D
-0.6%
1Y
n/a
Bonesupport Holding
Market Cap: SEK 14.8b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
BONEX
SEK 225.20
7D
1.2%
1Y
-26.4%
Kuros Biosciences
Market Cap: CHF 914.8m
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
KURN
CHF 23.06
7D
0.4%
1Y
-12.8%
MedinCell
Market Cap: €877.7m
Engages in the research and development of biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals in France.
MEDCL
€24.44
7D
-2.6%
1Y
54.0%
Insmed
Market Cap: US$29.4b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$132.57
7D
34.2%
1Y
8.7%
AnaptysBio
Market Cap: US$1.6b
A clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
ANAB
US$57.87
7D
5.0%
1Y
187.8%
Ardelyx
Market Cap: US$996.8m
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$3.94
7D
-21.4%
1Y
-29.6%
Ionis Pharmaceuticals
Market Cap: US$9.5b
A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
IONS
US$55.42
7D
0.6%
1Y
33.8%
Mereo BioPharma Group
Market Cap: US$43.5m
A biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States.
MREO
US$0.31
7D
-5.2%
1Y
-81.6%
Cutia Therapeutics
Market Cap: HK$843.0m
An investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong.
2487
HK$2.32
7D
-10.4%
1Y
-71.9%
WuXi XDC Cayman
Market Cap: HK$81.4b
An investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally.
2268
HK$64.25
7D
16.1%
1Y
12.3%
Ocumension Therapeutics
Market Cap: HK$4.5b
Engages in the research, discovery, development, and commercialization of ophthalmic therapies in China.
1477
HK$5.57
7D
6.7%
1Y
-47.2%
Capricor Therapeutics
Market Cap: US$223.0m
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$3.93
7D
-5.8%
1Y
-51.1%
Forum Markets
Market Cap: US$83.2m
A financial technology company, develops a blockchain-based platform focused on the acquisition, structuring, and tokenization of real-world assets worldwide.
FRMM
US$6.25
7D
7.0%
1Y
-93.9%
Aldeyra Therapeutics
Market Cap: US$91.1m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases.
ALDX
US$1.51
7D
-2.6%
1Y
-71.8%
DBV Technologies
Market Cap: €723.2m
A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.
DBV
€2.44
7D
5.6%
1Y
41.6%
Pharma Mar
Market Cap: €1.4b
A biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally.
PHM
€81.85
7D
3.9%
1Y
3.8%
Zevra Therapeutics
Market Cap: US$681.7m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$11.34
7D
7.8%
1Y
-3.6%
PharmaResearch
Market Cap: ₩4.3t
Operates as a biopharmaceutical company primarily in South Korea.
A214450
₩417,000.00
7D
8.5%
1Y
-37.7%
Bora Pharmaceuticals
Market Cap: NT$53.9b
Engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally.
6472
NT$423.50
7D
8.0%
1Y
-42.0%
Eton Pharmaceuticals
Market Cap: US$1.2b
A pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.
ETON
US$42.05
7D
-8.2%
1Y
142.8%
Kiniksa Pharmaceuticals International
Market Cap: US$6.0b
A biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
KNSA
US$77.80
7D
2.4%
1Y
137.3%
MindMaze Therapeutics Holding
Market Cap: CHF 35.6m
Operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally.
MMTX
CHF 0.23
7D
8.9%
1Y
n/a
Oxford Biomedica
Market Cap: UK£589.5m
A contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.
OXB
UK£4.87
7D
-14.0%
1Y
9.9%
AC Immune
Market Cap: US$226.7m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$2.54
7D
11.9%
1Y
18.1%
Arcutis Biotherapeutics
Market Cap: US$3.3b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$26.23
7D
0.8%
1Y
78.0%
CG Oncology
Market Cap: US$6.8b
A late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
CGON
US$77.03
7D
7.9%
1Y
208.7%
Codexis
Market Cap: US$161.3m
Provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China.
CDXS
US$1.48
7D
3.5%
1Y
-48.3%
Nuvation Bio
Market Cap: US$2.3b
A clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment.
NUVB
US$6.37
7D
-1.1%
1Y
174.6%